Universtiy of Colorado Hospital
Welcome,         Profile    Billing    Logout  
 6 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pollyea, Daniel Aaron
NCT03573024: Venetoclax and Azacitidine for Non-Elderly Adult Patients with Acute Myeloid Leukemia

Active, not recruiting
2
36
US
Azacitidine, Venetoclax
University of Colorado, Denver, AbbVie
Acute Myeloid Leukemia
06/26
06/27
OV-AML-1231, NCT06384261: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Recruiting
2
120
Europe, Canada, US
Cusatuzumab, OV-1001, Venetoclax, Azacitidine
OncoVerity, Inc.
Leukemia, Myeloid, Acute
01/27
06/27
NCT03564873: Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

Active, not recruiting
1/2
28
US
Omacetaxine, Phase 1, Azacitidine, Phase 2
University of Colorado, Denver
High Grade Myelodysplastic Syndromes
08/24
06/27
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active, not recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
NCT06429449: Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

Recruiting
1
30
US
Venetoclax, Venclexta, Venclyxto, Azacitidine, Onureg, Vidaza, Mitoxantrone, Novantrone
University of Colorado, Denver, The Leukemia and Lymphoma Society
Leukemia, Myeloid Leukemia, Monocytic Leukemia
12/26
11/27
NCT04914845: KPT-9274 in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Recruiting
1
40
US
KPT-9274
University of Colorado, Denver, Karyopharm Therapeutics Inc
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
02/26
02/27
20-1319.cc, NCT05287568: CC-486 and Venetoclax for Acute Myeloid Leukemia

Recruiting
1
35
US
Venetoclax, ABT-199, Abbvie, CC-486
University of Colorado, Denver, Bristol-Myers Squibb
AML
03/27
03/29
Schatz, Derek
NCT06232655: Cladribine Venetoclax in Monocytic AML

Recruiting
2
40
US
Cladribine, Mavenclad, Leustatin, Venetoclax, Venclyxto, Azacitidine, Vidaza, Onureg
University of Colorado, Denver, The Leukemia and Lymphoma Society
Acute Myeloid Leukemia
10/26
10/27
NCT04925193: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Active, not recruiting
2
18
US
Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone
University of Colorado, Denver, Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Multiple Myeloma in Relapse
08/24
11/25
ASTX660-03, NCT05403450: A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Active, not recruiting
1/2
132
Europe, US, RoW
Tolinapant, ASTX660, Decitabine + Cedazuridine, ASTX727
Taiho Oncology, Inc.
Relapsed/Refractory Peripheral T-cell Lymphoma
12/25
12/26
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active, not recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
NCT06429449: Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

Recruiting
1
30
US
Venetoclax, Venclexta, Venclyxto, Azacitidine, Onureg, Vidaza, Mitoxantrone, Novantrone
University of Colorado, Denver, The Leukemia and Lymphoma Society
Leukemia, Myeloid Leukemia, Monocytic Leukemia
12/26
11/27
NCT05535855: UCD19 CAR T Therapy in Adults with B-ALL and MRD Positivity in CR1

Recruiting
1
14
US
CD19 Directed CAR T Cell, UCD19 CAR T cells
University of Colorado, Denver
Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia
07/25
07/27
20-1319.cc, NCT05287568: CC-486 and Venetoclax for Acute Myeloid Leukemia

Recruiting
1
35
US
Venetoclax, ABT-199, Abbvie, CC-486
University of Colorado, Denver, Bristol-Myers Squibb
AML
03/27
03/29
NCT03093844: Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders

Active, not recruiting
N/A
150
US
Miltenyi CliniMACS® CD34 Reagent System
University of Colorado, Denver
Hematologic Disorders
11/24
02/27
NCT04545333: The clonoSEQ® Watch Registry

Terminated
N/A
465
US
clonoSEQ Assay
Adaptive Biotechnologies
Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
10/23
10/23
Dabdoub, Lauren
NCT05230810: Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Recruiting
1/2
40
US
Alpelisib, Piqray, Tucatinib, Tukysa, Fulvestrant, Faslodex,
Criterium, Inc., Novartis, Seagen Inc.
HER2-positive Metastatic Breast Cancer
08/24
06/25
McMahon, Christine
NCT06232655: Cladribine Venetoclax in Monocytic AML

Recruiting
2
40
US
Cladribine, Mavenclad, Leustatin, Venetoclax, Venclyxto, Azacitidine, Vidaza, Onureg
University of Colorado, Denver, The Leukemia and Lymphoma Society
Acute Myeloid Leukemia
10/26
10/27
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
NCT06429449: Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

Recruiting
1
30
US
Venetoclax, Venclexta, Venclyxto, Azacitidine, Onureg, Vidaza, Mitoxantrone, Novantrone
University of Colorado, Denver, The Leukemia and Lymphoma Society
Leukemia, Myeloid Leukemia, Monocytic Leukemia
12/26
11/27
KOMET-007, NCT05735184: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML

Recruiting
1
212
US
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine
Kura Oncology, Inc.
Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML with Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
05/26
05/27
20-1319.cc, NCT05287568: CC-486 and Venetoclax for Acute Myeloid Leukemia

Recruiting
1
35
US
Venetoclax, ABT-199, Abbvie, CC-486
University of Colorado, Denver, Bristol-Myers Squibb
AML
03/27
03/29
NCT05918913: Expanded Access Program for Revumenib

Available
N/A
US
Revumenib, SNDX-5613
Syndax Pharmaceuticals
Relapsed/Refractory Acute Leukemia
 
 

Download Options